Humana Inc (NYSE:HUM) insider Roy A. Beveridge sold 4,622 shares of the stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $341.06, for a total value of $1,576,379.32. Following the completion of the sale, the insider now directly owns 10,621 shares in the company, valued at approximately $3,622,398.26. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Shares of NYSE HUM traded down $10.27 during midday trading on Friday, hitting $306.00. 1,317,034 shares of the company’s stock were exchanged, compared to its average volume of 1,105,037. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.68 and a current ratio of 1.68. Humana Inc has a twelve month low of $242.00 and a twelve month high of $355.88. The firm has a market capitalization of $43.39 billion, a PE ratio of 26.13, a price-to-earnings-growth ratio of 1.50 and a beta of 0.99.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, topping the consensus estimate of $4.29 by $0.29. Humana had a return on equity of 19.10% and a net margin of 2.70%. The business had revenue of $14.21 billion for the quarter, compared to analyst estimates of $13.97 billion. During the same quarter last year, the company earned $3.39 EPS. On average, sell-side analysts forecast that Humana Inc will post 14.43 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 25th. Stockholders of record on Monday, December 31st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 0.65%. The ex-dividend date of this dividend is Friday, December 28th. Humana’s dividend payout ratio (DPR) is presently 11.96%.

A number of equities research analysts have issued reports on HUM shares. Argus increased their price target on Humana to $375.00 and gave the company a “buy” rating in a research report on Tuesday, September 4th. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $377.00 price target on the stock in a research report on Thursday, October 4th. Morgan Stanley increased their price target on Humana from $400.00 to $418.00 and gave the company a “buy” rating in a research report on Thursday, November 8th. BMO Capital Markets set a $390.00 price target on Humana and gave the company a “buy” rating in a research report on Thursday, November 8th. Finally, Bank of America increased their price target on Humana from $400.00 to $415.00 and gave the company a “buy” rating in a research report on Thursday, November 8th. Seven investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $352.10.

A number of large investors have recently added to or reduced their stakes in HUM. Capital International Investors grew its stake in Humana by 3,030.3% during the 3rd quarter. Capital International Investors now owns 8,217,296 shares of the insurance provider’s stock worth $2,781,719,000 after buying an additional 7,954,786 shares during the last quarter. FMR LLC grew its stake in Humana by 12.7% during the 2nd quarter. FMR LLC now owns 12,212,514 shares of the insurance provider’s stock worth $3,634,811,000 after buying an additional 1,374,030 shares during the last quarter. Renaissance Technologies LLC grew its stake in Humana by 14.1% during the 3rd quarter. Renaissance Technologies LLC now owns 3,174,800 shares of the insurance provider’s stock worth $1,074,733,000 after buying an additional 391,300 shares during the last quarter. Glenmede Trust Co. NA grew its stake in Humana by 153.7% during the 2nd quarter. Glenmede Trust Co. NA now owns 500,266 shares of the insurance provider’s stock worth $148,895,000 after buying an additional 303,080 shares during the last quarter. Finally, Ffcm LLC grew its stake in Humana by 5,891.4% during the 3rd quarter. Ffcm LLC now owns 288,544 shares of the insurance provider’s stock worth $14,968,000 after buying an additional 283,728 shares during the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Roy A. Beveridge Sells 4,622 Shares of Humana Inc (NYSE:HUM) Stock” was first posted by Marea Informative and is the property of of Marea Informative. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.mareainformativa.com/news/2018/12/08/humana-inc-hum-insider-sells-1576379-32-in-stock-updated-updated-updated.html.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Read More: Can individual investors take part in an IPO?

Insider Buying and Selling by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.